FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+56.06%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$630M
AUM Growth
+$630M
(+16%)
Cap. Flow
-$59.9M
Cap. Flow
% of AUM
-9.5%
Top 10 Holdings %
Top 10 Hldgs %
88.37%
Holding
27
New
1
Increased
5
Reduced
1
Closed
11
Top Buys
| 1 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$33.7M |
| 2 |
Nuvalent
NUVL
|
$21.1M |
| 3 |
Astria Therapeutics
ATXS
|
$14.7M |
| 4 |
Axsome Therapeutics
AXSM
|
$8.87M |
| 5 |
VRNA
Verona Pharma
VRNA
|
$5.14M |
Top Sells
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$31M |
| 2 |
Insmed
INSM
|
$28.8M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
$24.3M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$21.9M |
| 5 |
Acadia Pharmaceuticals
ACAD
|
$12.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$6.05B
| $155M | 24.61% | 2,011,647 +115,000 | +6% | +$8.87M |
|
|
2
Nuvalent
NUVL
$5.52B
| $83.1M | 13.18% | 2,788,981 +709,118 | +34% | +$21.1M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $75.1M | 11.92% | 2,875,526 +196,544 | +7% | +$5.14M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $52.7M | 8.35% | 239,443 +153,043 | +177% | +$33.7M |
|
5
Viridian Therapeutics
VRDN
$1.5B
| $40M | 6.35% | 1,369,623 | – | – |
|
6
Neurocrine Biosciences
NBIX
$13.8B
| $33.8M | 5.36% | 283,000 | – | – |
|
7
Cogent Biosciences
COGT
$1.69B
| $31.9M | 5.06% | 2,758,975 | – | – |
|
8
BioCryst Pharmaceuticals
BCRX
$1.74B
| $29.2M | 4.63% | 2,543,107 | – | – |
|
|
9
Astria Therapeutics
ATXS
$349M
| $28.3M | 4.49% | 1,901,397 +989,661 | +109% | +$14.7M |
|
10
argenx
ARGX
$43.6B
| $27.9M | 4.42% | 73,526 | – | – |
|
11
Terns Pharmaceuticals
TERN
$609M
| $20.8M | 3.29% | 2,040,000 -10,000 | -0.5% | -$102K |
|
12
Annexon
ANNX
$226M
| $17.4M | 2.75% | 3,358,563 | – | – |
|
13
Trevi Therapeutics
TRVI
$883M
| $11M | 1.74% | 5,696,515 | – | – |
|
|
DBVT
14
DBV Technologies
DBVT
$264M
| $10.8M | 1.71% | 7,064,964 | – | – |
|
15
Tyra Biosciences
TYRA
$675M
| $10.8M | 1.71% | 1,416,998 | – | – |
|
16
Enliven Therapeutics
ELVN
$1.2B
| $2.58M | 0.41% | +631,333 | New | +$2.58M |
|
|
17
Acadia Pharmaceuticals
ACAD
$4.38B
| – | – | -751,804 | Closed | -$12.3M |
|
|
ALLK
18
DELISTED
Allakos
ALLK
| – | – | -147,189 | Closed | -$901K |
|
|
AMRN
19
Amarin Corp
AMRN
$311M
| – | – | -5,584,837 | Closed | -$6.09M |
|
|
20
Enanta Pharmaceuticals
ENTA
$180M
| – | – | -469,264 | Closed | -$24.3M |
|
|
21
Insmed
INSM
$28.8B
| – | – | -1,336,368 | Closed | -$28.8M |
|
22
Iovance Biotherapeutics
IOVA
$807M
| – | – | -389,588 | Closed | -$3.73M |
|
23
Keros Therapeutics
KROS
$618M
| – | – | -272,498 | Closed | -$10.3M |
|
24
Olema Pharmaceuticals
OLMA
$375M
| – | – | -1,231,566 | Closed | -$3.4M |
|
25
Instil Bio
TIL
$182M
| – | – | -673,905 | Closed | -$3.26M |
|